Abstract: A vaccine is disclosed for the prophylaxis against pathogenic development of atherosclerotic plaque in a mammalian subject susceptible thereto which consists essentially of a multiplicity of killed whole-virus strains, selected from the group consisting of: Herpes Simplex Virus 1; Herpes Simplex Virus 2; Herpes Simplex Virus 6; Human Cytomegalovirus; and Epstein-Barr Virus; in combination with a pharmaceutically acceptable inert vaccine carrier or diluent.

Abstract: A composition is disclosed for generating an immune response against a herpes virus in an animal subject susceptible thereto, wherein the vaccine comprises a compound of the Formula:Val Asn Pro Arg Gly Gly Cys Phe Leu Gly Gly Gly Ala Lys Ala Gly 5 10 - 15 Gly Gly Gly Gly Arg Ala Ala Gly Gln Pro Arg Ala 20 25designated Sequence ID 1. The composition is especially effective in generating an immune response against Kaposi's sarcoma herpesvirus.

Abstract: A pharmaceutical composition is disclosed for the treatment against several herpes virus infections or atherosclerotic plaques in a mammalian subject suspectible thereto which comprises: (a) 10 to 30% by weight of the peptide of SEQ ID 2; (b) 10 to 30% by weight of the peptide of SEQ ID 4; 10 to 30% by weight of the peptide of SEQ ID 6; and (d) 10 to 30% by weight of the peptide of SEQ ID 8; in combination with a pharmaceutically acceptable inert carrier.

Abstract: A peptide is disclosed for detection of a herpe4s virus infection in an animal subject susceptible thereto, wherein the peptide comprises a compound of the Formula: ##STR1## designated Sequence ID 1.

Abstract: A composition is disclosed for controlling the stimulation of estrogen production, which comprises:(a) 15 to 120 parts by weight of one or more phytoestrogen compounds calculated as a free aglycon form of isoflavone;(b) up to 75 parts by weight of dried licorice root extract;(c) 10 to 80 parts by weight of a sedative selected from the group consisting of Valerian root dry extract, passion flower dry extract, and Ginseng root powder;(d) up to 50, preferably 10 to 20 parts by weight of beta-carotene;(e) up to 200, preferably 15 to 150 parts by weight of pyridoxine hydrochloride;(f) up to 50, preferably 12 to 30 parts by weight of Vitamin E;(g) up to 600, preferably 100 to 450 parts by weight of calcium contained in a biologically acceptable calcium salt;(h) up to 200, preferably 150 to 250 parts by weight of magnesium contained in a biologically acceptable magnesium salt;(i) up to 100, preferably 10 to 50 parts by weight of zinc contained in a biologically acceptable zinc salt;(j) up to 30 parts by weight of co

Abstract: A vaccine is disclosed for the prophylaxis against pathogenic development of atherosclerotic plaque in a mammalian subject susceptible thereto which comprises:(a) 10 to 30% by weight of the compound ##STR1## (b) 10 to 30% by weight of the compound ##STR2## (c) 10 to 30% by weight of the compound ##STR3## (d) 10 to 30% by weight of the compound ##STR4## in combination with a pharmaceutically acceptable inert carrier.

Abstract: A pharmaceutical composition is disclosed for the treatment of diabetic male sexual dysfunction, which comprises:(a) 45 to 60 parts by weight of one or more phytoestrogen compounds calculated as a free aglycon form of isoflavone;(b) 0 to 400, preferably 200 to 300 parts by weight of phosphatidyl choline;(c) 10 to 50 parts by weight of beta-sitosterol;(d) 0 to 300, preferably 30 to 100 parts by weight of Damiana leaf dry extract;(e) 0 to 15, preferably 1 to 3 parts by weight of Vitamin A;(f) 0 to 250, preferably 20 to 100 parts by weight of Vitamin B1;(g) 0 to 300, preferably 50 to 150 parts by weight of Vitamin B6;(h) 0 to 100, preferably 10 to 70 parts by weight of Vitamin E;(i) 0 to 300, preferably 50 to 200 parts by weight of calcium contained in a biologically acceptable calcium salt;(j) 0 to 750, preferably 300 to 500 parts by weight of magnesium contained in a biologically acceptable magnesium salt; and(k) 0 to 100, preferably 10 to 90 parts by weight of zinc contained in a biologically acceptable zinc

Abstract: A composition for the treatment or prevention of osteoporosis, is disclosed, which comprises:(a) 75 to 200 parts of one or more phytoestrogen compounds;(b) 0 to 100 parts of dried licorice root extract;(c) 300 to 600 parts of calcium contained in a biologically acceptable calcium salt;(d) 70 to 280 parts of magnesium contained in a biologically acceptable magnesium salt;(e) 4 to 25 parts of zinc contained in a biologically acceptable zinc salt;(f) 5 to 20 parts of beta-carotene;(g) 0.005 to 0.010 parts of Vitamin D as cholecalciferol; and(h) 6 to 12 parts of Vitamin E,in admixture with a biologically acceptable inert carrier. The new compositions are administered to a mammalian subject as either a pharmaceutical or as a dietary supplement.